Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism
The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
Abstract
This study examined potential differences in bleeding between apixaban and rivaroxaban, the most commonly utilized direct oral anticoagulants at the Richard L. Roudebush VA Medical Center. Additionally, the analysis included a comparison between observed and literature-reported bleeding rates. This retrospective chart review examined 452 (39%) Veterans receiving rivaroxaban and 716 (61%) Veterans receiving apixaban. Bleeding rates were expressed per 100 patient-years and the overall rates were analyzed as the primary analysis. Secondary objectives included comparisons based on indication and severity, as well as comparisons to literature-reported bleed rates, time to bleeding event, and location of the bleed. The analysis did not detect any statistically significant differences between apixaban and rivaroxaban in terms of overall, (ARR 0.90% per 100 patient-years, 95% CI - 0.58 to 2.38%, p > 0.05) major, (ARR 0.22% per 100 patient-years, 95% CI - 0.74 to 1.17%, p > 0.05) or non-major clinically relevant (ARR 0.35% per 100 patient-years, 95% CI - 0.57 to 1.27%, p > 0.05) bleeding. Observed bleeding for both rivaroxaban and apixaban in the Veteran population exceeded the rates reported by the literature when used for atrial fibrillation (1.96% vs. 0.15%, p < 0.05; 1.08% vs. 0.16%, p < 0.05) but the opposite was seen for long term venous thromboembolism (VTE) treatment (3.97% vs. 8.03%, p < 0.0001; 0.14% vs. 15.51%, p < 0.0001) or extended VTE prophylaxis (0.07% vs 5.98%, p < 0.…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A total of 5 studies were included for analysis: 1 study included a review of data from a thrombophilia clinic registry, 1 study included a review of retrospective data of veterans, and 3 were database studies from the United States and Denmark.”
From Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world (2019) · cites this paper as [11]
In the citing paper
“Various retrospective studies (database, registries) have been carried out looking at head-to-head comparisons between apixaban and rivaroxaban on VTE recurrence risk and bleeding risk. 8-11”
From Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world (2019) · cites this paper as [11]
In the citing paper
“In studies that had inclusion of both AF and VTE patients, data were extracted for patients with VTE only. 11”
From Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world (2019) · cites this paper as [11]
In the citing paper
“Although the 5 selected studies 8-11,14 assessed similar efficacy end points and outcomes, they were slightly different in terms of overall design and outcome definitions (Table 1).”
From Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world (2019) · cites this paper as [11]
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700518 · Cited by 787
Assessing bleeding risk in patients taking anticoagulants
Shoeb, M., & Fang, M. C. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0899-7 · Cited by 228
Smoking and the Risk of Hemorrhagic Stroke in Men
Kurth, T., Kase, C. S., Berger, K., Schaeffner, E. S., Buring, J. E., & Gaziano, J. M. (2003) · Stroke · doi:10.1161/01.str.0000065200.93070.32 · Cited by 192
Castellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2014) · JAMA · doi:10.1001/jama.2014.10538 · Cited by 162
Cited by
Aryal, M. R., Gosain, R., Donato, A., Yu, H., Katel, A., Bhandari, Y., Dhital, R., & Kouides, P. A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000572 · Cited by 62
“Our results are consistent with a prior network meta-analysis that indirectly compared these agents.4 Previous studies have shown apixaban to be safer in patients with advanced age, baseline active cancer, CKD, and provoked VTE.”
BackgroundMethodInfluentialHayek, M. E., Mansour, M., Ndetan, H. T., Burkes, Q., Corkern, R., Dulli, A., Hayek, R., Parvez, K., & Singh, S. (2021) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2021.03.007 · Cited by 37
“5% bleeding rate reported in the noneCOVID-19 population.(31) We noted no difficulties in bleeding cessation when anticoagulation was stopped in bleeding patients and no relation to mortality.”
Hwang, Y. J., Chang, H., Metkus, T. S., Andersen, K. M., Singh, S., Alexander, G. C., & Mehta, H. B. (2023) · Drug Safety · doi:10.1007/s40264-023-01388-z · Cited by 4
“Among more diverse cohorts that have included patients with atrial fibrillation or VTE, the risk of bleeding was also more favorable for apixaban compared with rivaroxaban in some studies [23, 24], while another study suggested the risk is similar between the two DOACs [18].”
Meretskyi, V., & Meretska, I. (2019) · Klinicheskaia khirurgiia · doi:10.26779/2522-1396.2019.06.73 · Cited by 2
Sychev, D. A., Sychev, I. N., Mirzaev, K. B., Rytkin, E., Ivashchenko, D. V., Bure, I. V., & Otdelenov, V. A. (2019) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn1214 · Cited by 1
Metadata
- Authors
- Howe, Z., Naville-Cook, C., & Cole, D.
- Affiliations
- Butler University (US)
- Richard L. Roudebush VA Medical Center (US)
- Corresponding author
- Howe, Zachary
- Venue
- Journal of Thrombosis and Thrombolysis
- Published
- 2018-11-17
- Volume
- 47
- Issue
- 2
- Pages
- 280-286
- ISSN
- 0929-5305 (ISSN-L)
- 1573-742X
- OpenAlex
- W2901182865
- Cited by
- 8
- References
- 16
- Citations by year
- 2026: 2 · 2023: 1 · 2021: 2 · 2019: 3
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Thrombosis and Thrombolysis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- apixaban, rivaroxaban, direct oral anticoagulants, bleeding risk, major bleeding, venous thromboembolism, atrial fibrillation, thromboprophylaxis, veterans, anticoagulant safety, veterans' health
- MeSH terms
- Rivaroxaban, Administration, Oral, Aged, Aged, 80 and over, Atrial Fibrillation, Blood Coagulation, Female, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Retrospective Studies, Risk Factors, Time Factors, United States, United States Department of Veterans Affairs, Treatment Outcome, Risk Assessment, Venous Thromboembolism, Veterans Health, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism. https://app.cochat.ai/papers/10.1007/s11239-018-1770-7
- The paper
- Howe, Z., Naville-Cook, C., & Cole, D. (2019). Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-018-1770-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.